Global multi-stakeholder endorsement of the MAFLD definition
Journal
The lancet. Gastroenterology & hepatology
Journal Volume
7
Journal Issue
5
Date Issued
2022-05
Author(s)
Méndez-Sánchez, Nahum
Bugianesi, Elisabetta
Gish, Robert G
Lammert, Frank
Tilg, Herbert
Nguyen, Mindie H
Sarin, Shiv K
Fabrellas, Núria
Zelber-Sagi, Shira
Fan, Jian-Gao
Shiha, Gamal
Targher, Giovanni
Zheng, Ming-Hua
Chan, Wah-Kheong
Vinker, Shlomo
Kawaguchi, Takumi
Castera, Laurent
Yilmaz, Yusuf
Korenjak, Marko
Spearman, C Wendy
Ungan, Mehmet
Palmer, Melissa
El-Shabrawi, Mortada
Gruss, Hans-Juergen
Dufour, Jean-François
Dhawan, Anil
Wedemeyer, Heiner
George, Jacob
Valenti, Luca
Fouad, Yasser
Romero-Gomez, Manuel
Eslam, Mohammed
Global multi-stakeholder consensus on the redefinition of fatty liver disease
Abstract
Comprising over 1000 signatories representative of multiple stakeholders, including hepatologists, internists, diabetologists, endocrinologists, paediatricians, primary-care providers, nephrologists, cardiologists, pathologists, patient advocates, nurses, nutritionists, and pharmaceutical experts from over 134 countries, we�Xthe undersigned�Xendorse both the name metabolic (dysfunction)-associated fatty liver disease (MAFLD) as an overarching term and its definition for fatty liver diseases associated with metabolic dysregulation. 1 , 2 , 3 We advocate for this change because it more accurately reflects the underlying pathogenesis of the disease than does the previously used term, non-alcoholic fatty liver disease (NAFLD). Furthermore, we believe that this designation will enhance our ability to advance the science of fatty liver disease and to improve patient care. 4 , 5 This open letter represents the voices of individuals and multiple stakeholders across the global liver health community; it is not intended to devalue any other initiative, but to complement and inform them.
Type
letter